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33 Application of anti-Pseudomonas aeruginosa immunoglobulins for
the diagnosis of cystic ﬁbrosis patients, in Hungary
K. Kristo´f1. 1Semmelweis University, Laboratory Medicine Institute, Microbiology,
Budapest, Hungary
Our investigation evaluated two anti-Pseudomonas aeruginosa based ELISA to
characterise CF patients at various infection status. The study involved 227 in-
dividuals, who are patients of the Hungarian Cystic Fibrosis Treatment Network.
The age distribution of these patients ranged from 0.2 to 45.9 years (mean 14.9)
consisting of 126 male and 101 female patients. Genetic studies were performed on
these patients (213/94%), at the time of diagnosis, their age spanned from 0.2 to
32.9 years (median 0.7). Two ELISA kits (Genesis Diagnostics Ltd) were used for
P. aeruginosa antibodies determination (IgA and IgG) in serum. Bacterial cultivation
conﬁrmed that 131 (57.7%) of the patients were positive for P. aeruginosa, prior our
studies. The ELISA showed that 64% of these patients had elevated (higher than
6U/mL) IgA or IgG levels, and 35% had high levels of both IgA and IgG. The
average IgA and IgG levels in their serum were 23.79 and 24.24U/mL. 90% of the
group with negative culture for P. aeruginosa had non-elevated speciﬁc Ig levels,
with the measured average IgA and IgG values of 2.1 and 2.5U/mL. However,
10% of this group (average age of 15.3 years) had elevated IgA and IgG level,
8.83 and 10.15U/mL. Eradication treatments were claimed to be successful by
clinicians for 52/114 (45%) patients, however 23/52 (44%) of them still showed
high Ig levels. Antibodies could be helpful in deﬁning the status of P. aeruginosa
infection/colonisation, the response and the type of treatment for CF. The ELISA
could also assist in the timing and duration of appropriate treatments for the most
beneﬁcial outcome.
34* Cystic ﬁbrosis newborn screened false-negative cohort:
a national long term survey
A. Munck1, A. Sicsic2, E. Houssin1, M. Roussey1, French CF Centres. 1AFDPHE,
Paris, France; 2FNORS, Paris, France
The French CF-NBS programme began in 2002 using IRT/DNA/IRT failsafe with
two ﬂow chart improvements.
Aims: (1) to evaluate the sensitivity over time (2) to characterize clinical and genetic
features of FN cases.
Methods: centralization of data from maternity wards, screening laboratories,
regional associations and CF centres was organized by AFDPHE with a yearly
questionnaire collecting all new CF cases.
Results: Over a 6 y period, among 4,331,539 NB, CF was diagnosed in 1060
including 48 FN identiﬁed during an 8 y follow-up period. The overall sensitivity
remained stable over time (95.5%). The screening programme failure concerned
initial and failsafe IRT (40, 4) or the notiﬁcation procedure (3 IRT, 1ST). Median age
at CF diagnosis was 13.8m with no statistical difference between those presenting
respiratory symptoms alone (15) or other symptoms (25) but was signiﬁcantly
delayed after a CF NBS sibling (7, 33m). Median ST value was 97mmol/L; normal
or intermediate values concerned 2 and 7 cases. Molecular analysis (CF30 Elucigene
kit, exhaustive genotyping for 31 alleles) identiﬁed 95% of mutant alleles.
Conclusion: It is the ﬁrst study with a nationwide yearly questionnaire sought to
identify all CF patients missed by NBS and a 100% reply rate. Over 25% of FN
had severe manifestations with damage due to delayed diagnosis and care. Given
a FN rate of 4.53%, involving classical CF and milder forms, careful assessment
and monitoring of the latter cohort will contribute to a better understanding of the
broad spectrum of CF. ST is consistently warranted given the clinical suspicion of
CF despite negative screening results and in older siblings of CF-screened infants.
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Introduction: Cystic Fibrosis (CF) is the most common lethal genetic disease in
white razes and its prevalence is about 1: 3000 newborn in developed countries.
Neonatal screening program is obligatory in Buenos Aires since 2000, but screening
for Cystic Fibrosis was incorporated in December 2002. It is organized in 3 levels:
13 maternities and 3 Children’s Hospitals were include in the1st level, 5 laboratories
in the 2nd level and one CF center in the 3rd level.
Objective: To determine the prevalence of the disease during the 7 years of the
program and describe the methods used for the diagnosis.
Methods: We included all newborns between December 2002 and December 2009.
Measurement was performed using the determination of Immunoreactive Trypsin
(IRT) in dried blood at day 2 of life. Those with values 70 ng/ml were taken a
second sample before 28 days of life. Those who had values above 60 ng/ml in the
second sample or did not attend on time and completed diagnostic scheme, a sweat
test was done.
Results: 244,889 newborns were screened and identiﬁed 33 patients with CF.
Homozygous p.508 del mutation was detected in 52% of those affected. The ﬁrst
and second determinations of IRT (×±SD) in the affected and normal newborns
were: 184±84 and 170±78; and 96±38 and 83.5±27, respectively. 1st and 2nd IRT
determination (x±DS) was done at 4±5 days and 16±10 days of age, respectively.
Age (x±SD) of the ﬁnal report was 79±55 days of life.
Conclusion: CF prevalence is 1: 7420 newborn in Buenos Aires City. IRT results
overlap between normal and affected children and sweat test is necessary to conﬁrm
the diagnosis.
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Objectives: A pilot newborn screening study for CF in northern Serbian Au-
tonomous Province of Vojvodina started in September 2009.
Methods: The newborns from 4 Maternity Hospitals were screened (63% of
all newborns born in Vojvodina from September 2009 to December 2010), as
voluntary. The applied screening protocol included the two stage IRT-IRT algorithm
(ﬁrst sample from Guthrie card positive if IRT above cut-off at the 99th centile,
and the second IRT if above 40 ng/ml) and sweat test for conﬁrmation/exclusion
diagnosis (conventional pilocarpine-iontophoresis). In cases of positive or borderline
sweat tests, mutation analysis was performed, the most frequent mutation in our
population, followed by the sequencing that is performed in two stages, if needed.
Results: From September 2009 to December 2010. 12000 newborns were screened,
ﬁrst IRT above cutt-off above 99.pct was found in 0.92%, second IRT above
40 ng/ml in 0.37% newborns. Three babies with CF were diagnosed. First IRT
133.8; 129.4; 175 ng/ml, respectively. Second IRT in ﬁrst case were not done, in
others: 129 and 236 ng/ml, respectively. Sweat test: 42.4 and 63.9mmol/L; 58.7 and
62.3mmol/L;.87and 96mmol/L, respectively. Two babies have F508del/F508del,
and third F508del/G126D genotype. Basic clinical evaluation were performed,
infants are followed and managed according to accepted published guidelines.
Conclusions: For the period of 15 months three babies with CF were diagnosed
in Province of Vojvodina, from 12 000 screened newborns. Screening is still in
progress. To determine the incidence of CF in our Province, we need to examine
more newborns.
